Review
Nature Reviews Drug Discovery 4, 988-1004 (December 2005) | doi:10.1038/nrd1902
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Bryan T. Hennessy1, Debra L. Smith1, Prahlad T. Ram1, Yiling Lu1 & Gordon B. Mills1 About the authors
Abstract
Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.
- View At a Glance
Author affiliations
- Department of Molecular Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Correspondence to: Gordon B. Mills1 Email: gmills@mdanderson.org
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugsBritish Journal of Cancer Original Article
See all 14 matches for Research
